Reblozyl® (luspatercept-aamt)

Reblozyl is covered for the FDA‑approved non‑oncology indication of anemia in adults (≥18) with transfusion‑dependent beta‑thalassemia and is excluded for patients <18, those who do not meet the transfusion burden criteria (≥6 units in the prior 24 weeks and no transfusion‑free period >35 days) or who have received prior gene therapy for TDT. Coverage requires hematologist prescription/consultation, initial authorization for 4 months (renewable for 12 months), dosing per guidance (start 1 mg/kg SC q3 weeks, may increase to 1.25 mg/kg), and reauthorization only if transfusion burden decreases by ≥2 RBC units over 6 months versus pretreatment baseline.

"Reblozyl is indicated for the treatment of anemia in adult patients with beta thalassemia who require regular red blood cell (RBC) transfusions."

Sign up to see full coverage criteria, indications, and limitations.